Duncan, G. W.

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

Vijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., et al. (2025) · The Lancet

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 181

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

Vijiaratnam, N., Girges, C., Auld, G., Chau, M., Maclagan, K., King, A., Skene, S., Chowdhury, K., Hibbert, S., Morris, H., et al. (2021) · BMJ Open

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 84

Vasovagal syncope in the older person: differences in presentation between older and younger patients

Duncan, G. W., Tan, M. P., Newton, J. L., Reeve, P., & Parry, S. W. (2010) · Age and Ageing

Cardiovascular Syncope and Autonomic DisordersVestibular and auditory disorders

Cited by 49

Progression of Neuropsychiatric Symptoms over Time in an Incident Parkinson’s Disease Cohort (ICICLE-PD)

Dlay, J. K., Duncan, G. W., Khoo, T. K., Williams-Gray, C. H., Breen, D. P., Barker, R. A., Burn, D. J., Lawson, R. A., & Yarnall, A. J. (2020) · Brain Sciences

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 44

The incidence of Parkinson's disease in the North-East of England

Duncan, G. W., Khoo, T. K., Coleman, S. Y., Brayne, C., Yarnall, A. J., O'Brien, J. T., Barker, R. A., & Burn, D. J. (2014) · Age and Ageing

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 32